LEXX
Lexaria Bioscience Corp. · Healthcare
1.01
5.19%(-0.06)
Market OpenLast Updated: — ET
52W L: $0.4652W H: $1.69
$1.01
CHG+0.22 (+27.38%)
H$1.06
L$0.65
VOL2.9M
LEXX (1h)
Lexaria Bioscience Corp. · Healthcare
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to recognize that the US Food and Drug Administration ("FDA") has approved Eli Lilly and Company's® Foundayo™ glucagon-like peptide-1 ("GLP-1") agonist (orforglipron) oral tablet for adult use in controlling obesity and weight-related medical conditions. "This latest approval from the FDA expands choices for Americans searching for the right weight control drug that best suits their needs," said Richard Christopher, CEO of Lexaria Bioscience Corp. "Expanded choices within the historically limited oral weight-loss drug category increases opportunities for Lexaria to partner with the leading companies in the pharmaceutical industry to implement DehydraTECH™ technology to improve patient experiences including through the potential for reduced side effects.
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects Kelowna, British Columbia – April 7, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to recognize that the US Food and Drug Administration (“FDA”) has approved Eli Lilly and Company's® Foundayo™ glucagon-like peptide-1 (“GLP-1”) agonist (orforglipron) oral tablet for adult use in controlling obesity and weight-related medical conditions.
Lexaria Bioscience (NASDAQ: LEXX - Get Free Report) is anticipated to announce its results before the market opens on Monday, April 13th. Analysts expect the company to announce earnings of ($0.0950) per share and revenue of $0.05 million for the quarter. Lexaria Bioscience (NASDAQ: LEXX - Get Free Report) last released its quarterly earnings data on Tuesday,
Contracts signed for Human Pilot Study #7 (GLP-1-H26-7) KELOWNA, BC / ACCESS Newswire / April 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its Human Pilot Study #7 (GLP-1-H26-7) that will evaluate 2 oral DehydraTECH-semaglutide ("DHT-sema") compositions against commercially available Wegovy® tablets (the "Study"). Contracts with the CRO have been signed and submissions are currently being prepared to obtain the required ethics approval from an independent review board.
Contracts signed for Human Pilot Study #7 (GLP-1-H26-7) Kelowna, British Columbia – April 1, 2026 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce the engagement of the contract research organization (“CRO”) to execute and report on its Human Pilot Study #7 (GLP-1-H26-7) that will evaluate 2 oral DehydraTECH-semaglutide (“DHT-sema”) compositions against commercially available Wegovy® tablets (the “Study”).
Lexaria receives 5 new patents including 2 for diabetes treatment utilizing GLP-1 drugs Kelowna, British Columbia – March 26, 2026 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property (“IP”) granted to the Company as a result of its ongoing research and development (“R&D”) programs. This new IP is recognized with the awarding of 5 new patents as detailed below.
BUNKA CHRISTOPHER
director
100,000 SH @ $0.00
2026-03-17
BUNKA CHRISTOPHER
director
11,900 SH @ $0.91
2025-07-30
BUNKA CHRISTOPHER
director
15,600 SH @ $0.92
2025-07-29
McKechnie William Edward
director
5,000 SH @ $0.91
2025-07-29
DOCHERTY JOHN MARTIN
director, officer: President & CSO
5,376 SH @ $0.93
2025-07-29
Carle Vanessa
officer: Secretary
750 SH @ $0.91
2025-07-29
CHRISTOPHER RICHARD
director, officer: Chief Executive Officer
15,000 SH @ $0.91
2025-07-29
CHRISTOPHER RICHARD
director, officer: Chief Executive Officer
150,000 SH @ $1.04
2025-05-15